Literature DB >> 8195802

A role for mast cells in the progression of Duchenne muscular dystrophy? Correlations in dystrophin-deficient humans, dogs, and mice.

J R Gorospe1, M D Tharp, J Hinckley, J N Kornegay, E P Hoffman.   

Abstract

Dystrophin deficiency has been shown to be the underlying cause of Duchenne muscular dystrophy. Although dystrophin-deficient homologous animal models have been identified (dog, mouse, and cat), the clinical expression of the biochemical defect is species-specific. Thus, while the genetics and biochemistry of Duchenne dystrophy is understood, the pathophysiological cascade leading to muscle weakness in only humans and dogs remains obscure. To begin to dissect the pathophysiology at the histological level, we undertook a systematic study of mast cells in normal and dystrophin-deficient muscle. Mast cells have been implicated in the development of fibrosis in other disorders, and progressive fibrosis has been hypothesized to mediate the failure of muscle regeneration in human and dog dystrophin deficiency. Our results show a strong correlation between mast cell content and localization, and the clinico-histopathological progression in humans, dogs and mice. The mast cell increases were disease specific: other dystrophic myopathies with normal dystrophin generally did not show substantial increases in mast cell content or degranulation. Our data suggest that mast cell accumulation and degranulation may cause the grouped necrosis characteristic of dystrophin deficiency in all species.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8195802     DOI: 10.1016/0022-510x(94)90050-7

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  26 in total

Review 1.  Positron emission tomography in paediatric cardiology.

Authors:  R M Quinlivan; R O Robinson; M N Maisey
Journal:  Arch Dis Child       Date:  1998-12       Impact factor: 3.791

2.  The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies.

Authors:  Mahmoud R Hussein; Sherifa A Hamed; Mohammed G Mostafa; Eman E Abu-Dief; Nageh Fouly Kamel; Mahmoud R Kandil
Journal:  Int J Exp Pathol       Date:  2006-12       Impact factor: 1.925

3.  Markers of degeneration and regeneration in Duchenne muscular dystrophy.

Authors:  E Abdel-Salam; I Abdel-Meguid; S S Korraa
Journal:  Acta Myol       Date:  2009-12

4.  Excessive collagen accumulation in dystrophic (mdx) respiratory musculature is independent of enhanced activation of the NF-kappaB pathway.

Authors:  K M Graham; R Singh; G Millman; G Malnassy; F Gatti; K Bruemmer; C Stefanski; H Curtis; J Sesti; C G Carlson
Journal:  J Neurol Sci       Date:  2010-05-13       Impact factor: 3.181

5.  Proinflammatory macrophages enhance the regenerative capacity of human myoblasts by modifying their kinetics of proliferation and differentiation.

Authors:  Maximilien Bencze; Elisa Negroni; Denis Vallese; Houda Yacoub-Youssef; Soraya Chaouch; Annie Wolff; Ahmed Aamiri; James P Di Santo; Bénédicte Chazaud; Gillian Butler-Browne; Wilson Savino; Vincent Mouly; Ingo Riederer
Journal:  Mol Ther       Date:  2012-10-16       Impact factor: 11.454

6.  Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy.

Authors:  Swarnali Acharyya; S Armando Villalta; Nadine Bakkar; Tepmanas Bupha-Intr; Paul M L Janssen; Micheal Carathers; Zhi-Wei Li; Amer A Beg; Sankar Ghosh; Zarife Sahenk; Michael Weinstein; Katherine L Gardner; Jill A Rafael-Fortney; Michael Karin; James G Tidball; Albert S Baldwin; Denis C Guttridge
Journal:  J Clin Invest       Date:  2007-03-22       Impact factor: 14.808

7.  Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy.

Authors:  S Armando Villalta; Hal X Nguyen; Bo Deng; Tomomi Gotoh; James G Tidball
Journal:  Hum Mol Genet       Date:  2008-11-07       Impact factor: 6.150

Review 8.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

Review 9.  Immune-mediated mechanisms potentially regulate the disease time-course of duchenne muscular dystrophy and provide targets for therapeutic intervention.

Authors:  Nicholas P Evans; Sarah A Misyak; John L Robertson; Josep Bassaganya-Riera; Robert W Grange
Journal:  PM R       Date:  2009-08       Impact factor: 2.298

10.  Partial least squares based identification of Duchenne muscular dystrophy specific genes.

Authors:  Hui-bo An; Hua-cheng Zheng; Li Zhang; Lin Ma; Zheng-yan Liu
Journal:  J Zhejiang Univ Sci B       Date:  2013-11       Impact factor: 3.066

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.